BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saunders RE, Goodship TH, Zipfel PF, Perkins SJ. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations. Hum Mutat 2006;27:21-30. [PMID: 16281287 DOI: 10.1002/humu.20268] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Saunders RE, Perkins SJ. CoagMDB: a database analysis of missense mutations within four conserved domains in five vitamin K-dependent coagulation serine proteases using a text-mining tool. Hum Mutat 2008;29:333-44. [PMID: 18058827 DOI: 10.1002/humu.20629] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
2 Okemefuna AI, Nan R, Gor J, Perkins SJ. Electrostatic interactions contribute to the folded-back conformation of wild type human factor H. J Mol Biol 2009;391:98-118. [PMID: 19505476 DOI: 10.1016/j.jmb.2009.06.010] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
3 Morgenthaler S, Thilly WG. A strategy to discover genes that carry multi-allelic or mono-allelic risk for common diseases: a cohort allelic sums test (CAST). Mutat Res 2007;615:28-56. [PMID: 17101154 DOI: 10.1016/j.mrfmmm.2006.09.003] [Cited by in Crossref: 353] [Cited by in F6Publishing: 306] [Article Influence: 22.1] [Reference Citation Analysis]
4 Schulte-Kemna L, Reister B, Bettac L, Ludwig U, Fürst D, Mytilineos J, Bergmann C, van Erp R, Schröppel B. Eculizumab in chemotherapy-induced thrombotic microangiopathy. Clin Nephrol Case Stud 2020;8:25-32. [PMID: 32318323 DOI: 10.5414/CNCS109836] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration--emerging pathogenetic and therapeutic concepts. Ann Med 2006;38:450-71. [PMID: 17101537 DOI: 10.1080/07853890600946724] [Cited by in Crossref: 362] [Cited by in F6Publishing: 341] [Article Influence: 24.1] [Reference Citation Analysis]
6 Edey MM, Mead PA, Saunders RE, Strain L, Perkins SJ, Goodship TH, Kanagasundaram NS. Association of a factor H mutation with hemolytic uremic syndrome following a diarrheal illness. Am J Kidney Dis 2008;51:487-90. [PMID: 18295065 DOI: 10.1053/j.ajkd.2007.08.030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
7 Perkins S, Okemefuna A, Nan R. Unravelling protein–protein interactions between complement factor H and C-reactive protein using a multidisciplinary strategy. Biochemical Society Transactions 2010;38:894-900. [DOI: 10.1042/bst0380894] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
8 Sim RB, Ferluga J, Al-Rashidi H, Abbow H, Schwaeble W, Kishore U. Complement factor H in its alternative identity as adrenomedullin-binding protein 1. Mol Immunol 2015;68:45-8. [PMID: 26597206 DOI: 10.1016/j.molimm.2015.06.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
9 Furtado PB, Huang CY, Ihyembe D, Hammond RA, Marsh HC, Perkins SJ. The partly folded back solution structure arrangement of the 30 SCR domains in human complement receptor type 1 (CR1) permits access to its C3b and C4b ligands. J Mol Biol 2008;375:102-18. [PMID: 18028942 DOI: 10.1016/j.jmb.2007.09.085] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
10 Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol 2009;10:728-33. [PMID: 19503104 DOI: 10.1038/ni.1755] [Cited by in Crossref: 238] [Cited by in F6Publishing: 228] [Article Influence: 18.3] [Reference Citation Analysis]
11 Johnson S, Taylor CM. Hemolytic Uremic Syndrome. In: Avner E, Harmon W, Niaudet P, Yoshikawa N, editors. Pediatric Nephrology. Berlin: Springer Berlin Heidelberg; 2009. pp. 1155-80. [DOI: 10.1007/978-3-540-76341-3_48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115:379-387. [PMID: 19861685 DOI: 10.1182/blood-2009-05-221549] [Cited by in Crossref: 239] [Cited by in F6Publishing: 214] [Article Influence: 18.4] [Reference Citation Analysis]
13 Thompson CL, Klein BE, Klein R, Xu Z, Capriotti J, Joshi T, Leontiev D, Lee KE, Elston RC, Iyengar SK. Complement factor H and hemicentin-1 in age-related macular degeneration and renal phenotypes. Human Molecular Genetics 2007;16:2135-48. [DOI: 10.1093/hmg/ddm164] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
14 Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB; European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009;24:687-96. [PMID: 18800230 DOI: 10.1007/s00467-008-0964-1] [Cited by in Crossref: 225] [Cited by in F6Publishing: 173] [Article Influence: 16.1] [Reference Citation Analysis]
15 Lengyel I, Peto T. Cure or cause: opposing roles for zinc in age-related macular degeneration. Expert Review of Ophthalmology 2014;3:1-4. [DOI: 10.1586/17469899.3.1.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
16 Bíró A, Prohászka Z, Füst G, Blaskó B. Determination of complement factor H functional polymorphisms (V62I, Y402H, and E936D) using sequence-specific primer PCR and restriction fragment length polymorphisms. Mol Diagn Ther 2006;10:303-10. [PMID: 17022693 DOI: 10.1007/BF03256205] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
17 Osborne AJ, Breno M, Borsa NG, Bu F, Frémeaux-Bacchi V, Gale DP, van den Heuvel LP, Kavanagh D, Noris M, Pinto S, Rallapalli PM, Remuzzi G, Rodríguez de Cordoba S, Ruiz A, Smith RJH, Vieira-Martins P, Volokhina E, Wilson V, Goodship THJ, Perkins SJ. Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Immunol 2018;200:2464-78. [PMID: 29500241 DOI: 10.4049/jimmunol.1701695] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 17.0] [Reference Citation Analysis]
18 Thomas A, Biswas A, Ivaskevicius V, Oldenburg J. Structural and functional influences of coagulation factor XIII subunit B heterozygous missense mutants. Mol Genet Genomic Med 2015;3:258-71. [PMID: 26247044 DOI: 10.1002/mgg3.138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
19 Perkins SJ, Nan R, Okemefuna AI, Li K, Khan S, Miller A. Multiple interactions of complement Factor H with its ligands in solution: a progress report. Adv Exp Med Biol 2010;703:25-47. [PMID: 20711705 DOI: 10.1007/978-1-4419-5635-4_3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
20 Hörl S, Banki Z, Huber G, Ejaz A, Müllauer B, Willenbacher E, Steurer M, Stoiber H. Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells. Haematologica 2013;98:1939-47. [PMID: 23850806 DOI: 10.3324/haematol.2013.089615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
21 Nan R, Gor J, Perkins SJ. Implications of the Progressive Self-association of Wild-type Human Factor H for Complement Regulation and Disease. Journal of Molecular Biology 2008;375:891-900. [DOI: 10.1016/j.jmb.2007.11.015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
22 Harboe M, Thorgersen EB, Mollnes TE. Advances in assay of complement function and activation. Adv Drug Deliv Rev 2011;63:976-87. [PMID: 21664392 DOI: 10.1016/j.addr.2011.05.010] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
23 Lapeyraque AL, Wagner E, Phan V, Clermont MJ, Merouani A, Frémeaux-Bacchi V, Goodship TH, Robitaille P. Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations. Pediatr Nephrol 2008;23:1363-6. [PMID: 18425537 DOI: 10.1007/s00467-008-0803-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
24 Perkins SJ, Nan R, Li K, Khan S, Miller A. Complement factor H-ligand interactions: self-association, multivalency and dissociation constants. Immunobiology 2012;217:281-97. [PMID: 22137027 DOI: 10.1016/j.imbio.2011.10.003] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 4.9] [Reference Citation Analysis]
25 Yunus A, Türker B, Ibrahim K. Complement Factor H Y403H Polymorphism in the Turkish Population. Balkan Journal of Medical Genetics 2010;13:41-5. [DOI: 10.2478/v10034-010-0025-5] [Reference Citation Analysis]
26 Gilbert HE, Asokan R, Holers VM, Perkins SJ. The 15 SCR Flexible Extracellular Domains of Human Complement Receptor Type 2 can Mediate Multiple Ligand and Antigen Interactions. Journal of Molecular Biology 2006;362:1132-47. [DOI: 10.1016/j.jmb.2006.08.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
27 Dunne OM, Gao X, Nan R, Gor J, Adamson PJ, Gordon DL, Moulin M, Haertlein M, Forsyth VT, Perkins SJ. A Dimerization Site at SCR-17/18 in Factor H Clarifies a New Mechanism for Complement Regulatory Control. Front Immunol 2020;11:601895. [PMID: 33552059 DOI: 10.3389/fimmu.2020.601895] [Reference Citation Analysis]
28 Perkins SJ. Genetic and Protein Structural Evaluation of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. Adv Chronic Kidney Dis 2020;27:120-127.e4. [PMID: 32553244 DOI: 10.1053/j.ackd.2020.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Sullivan M, Erlic Z, Hoffmann MM, Arbeiter K, Patzer L, Budde K, Hoppe B, Zeier M, Lhotta K, Rybicki LA, Bock A, Berisha G, Neumann HP. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet 2010;74:17-26. [PMID: 20059470 DOI: 10.1111/j.1469-1809.2009.00554.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
30 Johnson S, Taylor CM. What's new in haemolytic uraemic syndrome? Eur J Pediatr 2008;167:965-71. [PMID: 18575887 DOI: 10.1007/s00431-008-0745-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
31 Morgan HP, Mertens HD, Guariento M, Schmidt CQ, Soares DC, Svergun DI, Herbert AP, Barlow PN, Hannan JP. Structural analysis of the C-terminal region (modules 18-20) of complement regulator factor H (FH). PLoS One 2012;7:e32187. [PMID: 22389686 DOI: 10.1371/journal.pone.0032187] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
32 Mukai S, Hidaka Y, Hirota-kawadobora M, Matsuda K, Fujihara N, Takezawa Y, Kubota S, Koike K, Honda T, Yamauchi K. Factor H gene variants in Japanese: Its relation to atypical hemolytic uremic syndrome. Molecular Immunology 2011;49:48-55. [DOI: 10.1016/j.molimm.2011.07.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
33 Olivar R, Luque A, Cárdenas-Brito S, Naranjo-Gómez M, Blom AM, Borràs FE, Rodriguez de Córdoba S, Zipfel PF, Aran JM. The Complement Inhibitor Factor H Generates an Anti-Inflammatory and Tolerogenic State in Monocyte-Derived Dendritic Cells. J Immunol. 2016;196:4274-4290. [PMID: 27076676 DOI: 10.4049/jimmunol.1500455] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
34 Cantsilieris S, Nelson BJ, Huddleston J, Baker C, Harshman L, Penewit K, Munson KM, Sorensen M, Welch AE, Dang V, Grassmann F, Richardson AJ, Guymer RH, Graves-Lindsay TA, Wilson RK, Weber BHF, Baird PN, Allikmets R, Eichler EE. Recurrent structural variation, clustered sites of selection, and disease risk for the complement factor H (CFH) gene family. Proc Natl Acad Sci U S A 2018;115:E4433-42. [PMID: 29686068 DOI: 10.1073/pnas.1717600115] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
35 Goodship TH, Pappworth IY, Toth T, Denton M, Houlberg K, McCormick F, Warland D, Moore I, Hunze EM, Staniforth SJ. Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol Immunol. 2012;52:200-206. [PMID: 22721707 DOI: 10.1016/j.molimm.2012.05.009] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
36 Schneider MC, Exley RM, Ram S, Sim RB, Tang CM. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol 2007;15:233-40. [PMID: 17398100 DOI: 10.1016/j.tim.2007.03.005] [Cited by in Crossref: 99] [Cited by in F6Publishing: 96] [Article Influence: 6.6] [Reference Citation Analysis]
37 Reza MJ, Kamble A, Ahmad M, Krishnasastry MV, Sahu A. Dissection of functional sites in herpesvirus saimiri complement control protein homolog. J Virol 2013;87:282-95. [PMID: 23077301 DOI: 10.1128/JVI.01867-12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
38 Sjöberg AP, Trouw LA, Clark SJ, Sjölander J, Heinegård D, Sim RB, Day AJ, Blom AM. The Factor H Variant Associated with Age-related Macular Degeneration (His-384) and the Non-disease-associated Form Bind Differentially to C-reactive Protein, Fibromodulin, DNA, and Necrotic Cells. Journal of Biological Chemistry 2007;282:10894-900. [DOI: 10.1074/jbc.m610256200] [Cited by in Crossref: 101] [Cited by in F6Publishing: 69] [Article Influence: 6.7] [Reference Citation Analysis]
39 Xing C, Sivakumaran TA, Wang JJ, Rochtchina E, Joshi T, Smith W, Mitchell P, Iyengar SK. Complement factor H polymorphisms, renal phenotypes and age-related macular degeneration: the Blue Mountains Eye Study. Genes Immun 2008;9:231-9. [PMID: 18340363 DOI: 10.1038/gene.2008.10] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
40 Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Remuzzi G, Strain L, Goodship TH. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant. 2006;6:1948-1952. [PMID: 16889549 DOI: 10.1111/j.1600-6143.2006.01375.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 5.9] [Reference Citation Analysis]
41 Rattner A, Nathans J. Macular degeneration: recent advances and therapeutic opportunities. Nat Rev Neurosci 2006;7:860-72. [PMID: 17033682 DOI: 10.1038/nrn2007] [Cited by in Crossref: 136] [Cited by in F6Publishing: 125] [Article Influence: 8.5] [Reference Citation Analysis]
42 Delvasto-Nuñez L, Jongerius I, Zeerleder S. It takes two to thrombosis: Hemolysis and complement. Blood Rev 2021;:100834. [PMID: 33985796 DOI: 10.1016/j.blre.2021.100834] [Reference Citation Analysis]
43 Rodriguez E, Rallapalli PM, Osborne AJ, Perkins SJ. New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep 2014;34:e00146. [PMID: 25188723 DOI: 10.1042/BSR20140117] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 5.9] [Reference Citation Analysis]
44 Taylor CM, Machin S, Wigmore SJ, Goodship TH; working party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010;148:37-47. [PMID: 19821824 DOI: 10.1111/j.1365-2141.2009.07916.x] [Cited by in Crossref: 149] [Cited by in F6Publishing: 113] [Article Influence: 11.5] [Reference Citation Analysis]
45 Lengyel I, Flinn JM, Peto T, Linkous DH, Cano K, Bird AC, Lanzirotti A, Frederickson CJ, van Kuijk FJ. High concentration of zinc in sub-retinal pigment epithelial deposits. Exp Eye Res 2007;84:772-80. [PMID: 17313944 DOI: 10.1016/j.exer.2006.12.015] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 5.7] [Reference Citation Analysis]
46 Osborne AJ, Nan R, Miller A, Bhatt JS, Gor J, Perkins SJ. Two distinct conformations of factor H regulate discrete complement-binding functions in the fluid phase and at cell surfaces. J Biol Chem 2018;293:17166-87. [PMID: 30217822 DOI: 10.1074/jbc.RA118.004767] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
47 Barden N, Harvey M, Gagné B, Shink E, Tremblay M, Raymond C, Labbé M, Villeneuve A, Rochette D, Bordeleau L, Stadler H, Holsboer F, Müller-myhsok B. Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet 2006;141B:374-82. [DOI: 10.1002/ajmg.b.30303] [Cited by in Crossref: 151] [Cited by in F6Publishing: 143] [Article Influence: 9.4] [Reference Citation Analysis]
48 Watson R, Wearmouth E, McLoughlin AC, Jackson A, Ward S, Bertram P, Bennaceur K, Barker CE, Pappworth IY, Kavanagh D, Lea SM, Atkinson JP, Goodship TH, Marchbank KJ. Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2015;63:287-96. [PMID: 25150608 DOI: 10.1016/j.molimm.2014.07.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
49 Goodship TH. Atypical HUS and Complement Dysregulation. JASN 2006;17:1775-6. [DOI: 10.1681/asn.2006050521] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
50 Kelly U, Yu L, Kumar P, Ding JD, Jiang H, Hageman GS, Arshavsky VY, Frank MM, Hauser MA, Rickman CB. Heparan sulfate, including that in Bruch's membrane, inhibits the complement alternative pathway: implications for age-related macular degeneration. J Immunol 2010;185:5486-94. [PMID: 20876352 DOI: 10.4049/jimmunol.0903596] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
51 Gavriilaki E, Asteris PG, Touloumenidou T, Koravou EE, Koutra M, Papayanni PG, Karali V, Papalexandri A, Varelas C, Chatzopoulou F, Chatzidimitriou M, Chatzidimitriou D, Veleni A, Grigoriadis S, Rapti E, Chloros D, Kioumis I, Kaimakamis E, Bitzani M, Boumpas D, Tsantes A, Sotiropoulos D, Sakellari I, Kalantzis IG, Parastatidis ST, Koopialipoor M, Cavaleri L, Armaghani DJ, Papadopoulou A, Brodsky RA, Kokoris S, Anagnostopoulos A. Genetic justification of severe COVID-19 using a rigorous algorithm. Clin Immunol 2021;226:108726. [PMID: 33845193 DOI: 10.1016/j.clim.2021.108726] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
52 Atkinson JP, Goodship TH. Complement factor H and the hemolytic uremic syndrome. J Exp Med 2007;204:1245-8. [PMID: 17548524 DOI: 10.1084/jem.20070664] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
53 Okemefuna AI, Gilbert HE, Griggs KM, Ormsby RJ, Gordon DL, Perkins SJ. The regulatory SCR-1/5 and cell surface-binding SCR-16/20 fragments of factor H reveal partially folded-back solution structures and different self-associative properties. J Mol Biol 2008;375:80-101. [PMID: 18005991 DOI: 10.1016/j.jmb.2007.09.026] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
54 Loeven MA, Rops AL, Berden JH, Daha MR, Rabelink TJ, van der Vlag J. The role of heparan sulfate as determining pathogenic factor in complement factor H-associated diseases. Molecular Immunology 2015;63:203-8. [DOI: 10.1016/j.molimm.2014.08.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
55 Hageman GS, Hancox LS, Taiber AJ, Gehrs KM, Anderson DH, Johnson LV, Radeke MJ, Kavanagh D, Richards A, Atkinson J, Meri S, Bergeron J, Zernant J, Merriam J, Gold B, Allikmets R, Dean M. Extended haplotypes in the complement factor H ( CFH ) and CFH‐related ( CFHR ) family of genes protect against age‐related macular degeneration: Characterization, ethnic distribution and evolutionary implications. Annals of Medicine 2009;38:592-604. [DOI: 10.1080/07853890601097030] [Cited by in Crossref: 166] [Cited by in F6Publishing: 72] [Article Influence: 12.8] [Reference Citation Analysis]
56 Klein R, Knudtson MD, Lee KE, Klein BE. Serum cystatin C level, kidney disease markers, and incidence of age-related macular degeneration: the Beaver Dam Eye Study. Arch Ophthalmol 2009;127:193-9. [PMID: 19204238 DOI: 10.1001/archophthalmol.2008.551] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
57 Gnappi E, Allinovi M, Vaglio A, Bresin E, Sorosina A, Pilato FP, Allegri L, Manenti L. Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case. Pediatr Nephrol 2012;27:1995-9. [DOI: 10.1007/s00467-012-2210-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
58 Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods. 2011;365:8-26. [PMID: 21215749 DOI: 10.1016/j.jim.2010.12.020] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 9.8] [Reference Citation Analysis]
59 Zipfel PF, Skerka C. Complement dysfunction in hemolytic uremic syndrome. Curr Opin Rheumatol 2006;18:548-55. [PMID: 16896298 DOI: 10.1097/01.bor.0000240370.47336.ae] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
60 Kouser L, Abdul-Aziz M, Nayak A, Stover CM, Sim RB, Kishore U. Properdin and factor h: opposing players on the alternative complement pathway “see-saw”. Front Immunol. 2013;4:93. [PMID: 23630525 DOI: 10.3389/fimmu.2013.00093] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
61 Fernando AN, Furtado PB, Clark SJ, Gilbert HE, Day AJ, Sim RB, Perkins SJ. Associative and structural properties of the region of complement factor H encompassing the Tyr402His disease-related polymorphism and its interactions with heparin. J Mol Biol 2007;368:564-81. [PMID: 17362990 DOI: 10.1016/j.jmb.2007.02.038] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
62 Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, Johnson LV. Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci U S A 2006;103:17456-61. [PMID: 17079491 DOI: 10.1073/pnas.0606234103] [Cited by in Crossref: 143] [Cited by in F6Publishing: 134] [Article Influence: 8.9] [Reference Citation Analysis]
63 Hörl S, Bánki Z, Huber G, Ejaz A, Windisch D, Muellauer B, Willenbacher E, Steurer M, Stoiber H. Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity. Leukemia 2013;27:2200-8. [PMID: 23760402 DOI: 10.1038/leu.2013.169] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
64 Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26:41-57. [PMID: 20556434 DOI: 10.1007/s00467-010-1556-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
65 Saunders RE, Abarrategui-Garrido C, Frémeaux-Bacchi V, Goicoechea de Jorge E, Goodship TH, López Trascasa M, Noris M, Ponce Castro IM, Remuzzi G, Rodríguez de Córdoba S, Sánchez-Corral P, Skerka C, Zipfel PF, Perkins SJ. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat 2007;28:222-34. [PMID: 17089378 DOI: 10.1002/humu.20435] [Cited by in Crossref: 127] [Cited by in F6Publishing: 114] [Article Influence: 8.5] [Reference Citation Analysis]